PULM logo

PULMATRIX INC

PULMNASDAQ
πŸ† #4989 by market capEarnings Apr 1US Equity
$1.27β–Ό $0.15 (βˆ’10.56%)
Market closed Β· at close
πŸ””
Track PULM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 10.6%
7dβ–Ό 5.2%
14dβ–Ό 13.6%
30dβ–Ό 7.0%
ytdβ–Ό 42.8%
1yβ–Ό 72.9%
🏦Market Cap
$5M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-100.0%
Declining
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.20 – $1.42
52-Week Range
$1.06 – $4.94
Volume (shares)
90,741
Avg Volume (shares)
β€”
Shares Outstanding
3.7M
Next Earnings
2027-04-01

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-1.1
P/S Ratio
0.0x
EPS (TTM)
$-1.19
Dividend Yield
0.00%
Dilution (1yr)
+0.0%
PULM logo

PULMATRIX INC

PULM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.2%β–Ό βˆ’107.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$5Mβ–Ό βˆ’47.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’51.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.7Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mβ–Ό βˆ’$5M YoY
StockOtter Β· stockotter.space

About PULMATRIX INC

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireΒ·5d ago

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Merger withΒ Eos SENOLYTIX expected to close by end of the year FRAMINGHAM, Mass., Nov. 17, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix", the "Company" or "our") (Nasdaq: PULM), a biopharmaceutical company that has f

GlobeNewsWireΒ·13d ago

Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference

Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patients with Sarcopenia

GlobeNewsWireΒ·23d ago

Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-Enabling Development

GlobeNewsWireΒ·Oct 22

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches β€œTeam Speedy” to Let the Public Follow Its Longest-Lived Mouse

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) β€œSpeedy,” a PTC-2105-trea

Defense WorldΒ·Oct 20

Pulmatrix (NASDAQ:PULM) Share Price Breaks Below Fifty Day Moving Average – Here’s What Happened

Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) shares crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.50 and traded as low as $1.35. Pulmatrix shares

Defense WorldΒ·Sep 27

Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%

Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 55,391 shares, an increase of 174.2% fr